Fast Track Designation highlights potential of amezalpat to address unmet need for patients with HCC. Amezalpat builds ...

CSL Behring's gene therapy Hemgenix four years post-infusion data continue to show sustained efficacy and safety in adults with haemophilia B: King of Prussia, Pennsylvania Monday ...

New viruses and existing viruses acquiring greater pathology and infectivity are bound to keep ... as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular ...

Discover how integrating advanced imaging, digital pathology, and molecular analysis, can refine fibrosis staging and ...

BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma ... pathologic microvascular invasion, and histologic differentiation also were similar between the two groups (Table 1). At the time ...

Exclusion criteria were as follows: preoperative anti-cancer therapies, such as radiofrequency ablation, transarterial chemoembolization and chemotherapy; mixed tumor histology ... of West China ...

Hepatocellular carcinoma frequently shows early invasion into blood vessels ... We also examined liver tissue from three subjects with normal liver histology. The liver specimens were obtained by ...

aDepartment of Medicine, Queen Mary Hospital, The University of Hong Kong, Hong Kong, China bDepartment of Pathology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China ...

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the ...

Amezalpat is an investigational oral, small molecule, selective peroxisome proliferator-activated receptor-alpha antagonist.